Antioxidant treatments for schizophrenia (Q24186162)

20 October 2023

5

Flávio Kapczinski

Flávio

Kapczinski

1 reference

20 October 2023

3

Ana C Andreazza

Ana C

Andreazza

1 reference

20 October 2023

2

Olivia

Dean

Olivia Dean

1 reference

20 October 2023

Pedro V S Magalhães

1

Pedro V S

Magalhães

1 reference

26848926

Cochrane Database of Systematic Reviews

20 October 2023

publication date

5 February 2016

0 references

published in

0 references

cites work

Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

A double-blind trial of adjunctive allopurinol for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Treatment of long-term tardive dyskinesia with vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Haloperidol-induced extrapyramidal reaction: lack of protective effect by vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Treatment of tardive dyskinesia with vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Neuroprogression: pathways to progressive brain changes in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Clinical implications of Brief Psychiatric Rating Scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Is the superior efficacy of new generation antipsychotics an artifact of LOCF?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Antipsychotic drug effects on brain morphology in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Oxidative stress in psychiatric disorders: evidence base and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Size of burden of schizophrenia and psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Vitamin E for neuroleptic-induced tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Free radicals and antioxidants in normal physiological functions and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

7 January 2021

A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

7 January 2021

Long-term treatment effects of vitamin E for tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

1 reference

7 January 2021

Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

7 January 2021

Lack of effect of vitamin E on serum creatine phosphokinase in patients with long-term tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

7 January 2021

Vitamin E in the treatment of tardive dyskinesia: a replication study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

7 January 2021

Behavioral effects of drug therapy on psychogeriatric inpatients. II. Multivitamin supplement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

7 January 2021

Vitamin E in the treatment of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

7 January 2021

Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

7 January 2021

Vitamin E treatment of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

7 January 2021

Desoxycortone acetate and ascorbic acid in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

7 January 2021

Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008919.PUB2

7 January 2021